Sellas Life Sciences faces high risk in the Phase 3 REGAL AML trial for GPS. Click here to know why I rate the SLS stock a ...
We came across a bullish thesis on Sellas Life Sciences Group Inc (SLS) on ValueInvestorsClub by ContraMundem. In this article we will summarize the bulls’ thesis on SLS. Sellas Life Sciences shares ...
12d
A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement
SELLAS Life Sciences Group (SLS) has entered an agreement with IMPACT-AML, a pan-European clinical network, to run a new study of its CDK9 inhibitor SLS009 in high-risk newly diagnosed acute myeloid ...
SELLAS Life Sciences (NASDAQ:SLS) traded sharply lower on Thursday after the New York-based biotech released interim results from its Phase 3 REGAL trial for its lead asset, galinpepimut-S (GPS), ...
SELLAS Life Sciences Group recently reported that its Phase 3 REGAL trial of galinpepimut‑S (GPS) in Acute Myeloid Leukemia had reached 72 of the 80 overall-survival events required for final analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results